IGM Historical Financial Ratios
| IGMS Stock | USD 9.25 0.24 2.53% |
IGM Biosciences is lately reporting on over 121 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 2.25 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate IGM Biosciences financial condition quickly.
IGM |
About IGM Financial Ratios Analysis
IGM BiosciencesFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate IGM Biosciences investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on IGM financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across IGM Biosciences history.
IGM Biosciences Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing IGM Biosciences stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on IGM Biosciences sales, a figure that is much harder to manipulate than other IGM Biosciences multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Research And Ddevelopement To Revenue
The ratio of a company's research and development expenses to its total revenue, indicating how much of the revenue is invested back into developing new products or services.Capex To Revenue
The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.Most ratios from IGM Biosciences' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into IGM Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IGM Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For more information on how to buy IGM Stock please use our How to Invest in IGM Biosciences guide.At this time, IGM Biosciences' Tangible Book Value Per Share is comparatively stable compared to the past year. Shareholders Equity Per Share is likely to gain to 4.08 in 2024, whereas Operating Cash Flow Per Share is likely to drop (3.86) in 2024.
IGM Biosciences fundamentals Correlations
Click cells to compare fundamentals
IGM Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
IGM Biosciences fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | (3.2) | (14.4) | (2.78) | (1.23) | 2.14 | 2.25 | |
| Book Value Per Share | 26.71 | 12.42 | 7.32 | 6.91 | 3.89 | 4.08 | |
| Free Cash Flow Yield | (1.96) | (0.14) | (0.0312) | (0.0227) | (0.47) | (0.49) | |
| Operating Cash Flow Per Share | (5.02) | (2.19) | (3.71) | (0.14) | (3.67) | (3.86) | |
| Capex To Depreciation | 3.91 | 17.08 | 2.95 | 1.68 | 1.5 | 1.42 | |
| Pb Ratio | (3.2) | (14.4) | (2.78) | (1.23) | 2.14 | 2.25 | |
| Free Cash Flow Per Share | (47.55) | (5.28) | (2.76) | (4.11) | (0.39) | (3.91) | |
| Roic | 0.42 | 0.44 | 0.46 | 0.39 | (1.26) | (1.2) | |
| Net Income Per Share | (4.73) | (2.61) | (4.8) | (5.16) | (4.71) | (4.95) | |
| Payables Turnover | 0.76 | 0.45 | 1.38 | 4.22 | 6.24 | 6.55 | |
| Cash Per Share | 24.97 | 11.91 | 6.86 | 10.28 | 6.46 | 7.52 | |
| Pocfratio | (7.61) | (40.34) | (7.9) | (120.74) | (2.26) | (2.37) | |
| Capex To Operating Cash Flow | (0.0518) | (0.26) | (0.11) | (1.74) | (0.0644) | (0.0676) | |
| Pfcf Ratio | (7.23) | (32.01) | (7.14) | (44.0) | (2.12) | (2.23) | |
| Days Payables Outstanding | 482.96 | 808.8 | 263.87 | 86.48 | 58.47 | 55.55 | |
| Income Quality | 0.88 | 1.05 | 0.83 | 0.75 | 0.0265 | 0.78 | |
| Roe | 0.4 | 0.43 | 0.45 | 0.37 | (1.21) | (1.15) | |
| Ev To Operating Cash Flow | (7.14) | (36.94) | (7.06) | (107.06) | (1.89) | (1.98) | |
| Pe Ratio | (8.07) | (33.8) | (6.11) | (3.3) | (1.76) | (1.85) | |
| Return On Tangible Assets | (0.16) | (0.2) | (0.54) | (0.42) | (0.58) | (0.61) | |
| Ev To Free Cash Flow | (6.79) | (29.31) | (6.38) | (39.02) | (1.77) | (1.86) | |
| Earnings Yield | (0.12) | (0.0296) | (0.16) | (0.3) | (0.57) | (0.6) | |
| Net Debt To E B I T D A | 0.52 | 2.94 | 0.66 | 0.36 | 0.28 | 0.54 | |
| Current Ratio | 26.04 | 21.65 | 8.67 | 9.81 | 8.18 | 8.61 | |
| Tangible Book Value Per Share | 26.71 | 12.42 | 7.32 | 6.91 | 3.89 | 4.08 | |
| Graham Number | 35.61 | 18.99 | 33.78 | 40.07 | 20.29 | 19.28 | |
| Shareholders Equity Per Share | (11.92) | (6.13) | (10.57) | (13.84) | 3.89 | 4.08 | |
| Debt To Equity | (0.0232) | (0.0141) | (0.009386) | (0.0101) | 0.0287 | 0.0301 | |
| Capex Per Share | 0.26 | 0.57 | 0.4 | 0.25 | 0.24 | 0.22 | |
| Graham Net Net | 21.96 | 11.04 | 5.27 | 4.84 | 2.25 | 2.36 | |
| Debt To Assets | 0.009501 | 0.006527 | 0.0111 | 0.0113 | 0.0138 | 0.0131 | |
| Enterprise Value Over E B I T D A | (7.89) | (31.96) | (5.57) | (2.82) | (1.43) | (1.5) | |
| Short Term Coverage Ratios | (18.17) | (25.24) | (37.45) | (1.01) | (32.95) | (34.6) | |
| Price Earnings Ratio | (8.07) | (33.8) | (6.11) | (3.3) | (1.76) | (1.85) | |
| Price Book Value Ratio | (3.2) | (14.4) | (2.78) | (1.23) | 2.14 | 2.25 | |
| Price Earnings To Growth Ratio | 0.0888 | 0.75 | (0.0728) | (0.44) | 0.2 | 0.21 | |
| Days Of Payables Outstanding | 482.96 | 808.8 | 263.87 | 86.48 | 58.47 | 55.55 | |
| Price To Operating Cash Flows Ratio | (7.61) | (40.34) | (7.9) | (120.74) | (2.26) | (2.37) | |
| Price To Free Cash Flows Ratio | (7.23) | (32.01) | (7.14) | (44.0) | (2.12) | (2.23) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for IGM Stock Analysis
When running IGM Biosciences' price analysis, check to measure IGM Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IGM Biosciences is operating at the current time. Most of IGM Biosciences' value examination focuses on studying past and present price action to predict the probability of IGM Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IGM Biosciences' price. Additionally, you may evaluate how the addition of IGM Biosciences to your portfolios can decrease your overall portfolio volatility.